Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Axcella Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11309
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Axcella Health Inc (Axcella), formerly Pronutria Biosciences Inc is a developer of disease-specific amino acid profiles. The company’s lead clinical-stage candidates AXA are based on cell-specific sets of amino acids that regulate multiple biological pathways. Its amino acid therapies helps in treating orphan diseases in muscle, neurological, metabolic and liver settings, which include myotonic dystrophy, intractable epilepsy syndromes, pediatric nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, sarcopenia and other disease populations. Axcella conducts human signal seeking and confirming studies to understand the impact of various AXA candidates on human liver biology. The company uses a proprietary platform to identify the amino acid profile associated with a medical condition and de-risk the clinical development process. Axcella is headquartered in Cambridge, Massachusetts, the US.

Axcella Health Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Axcella Health Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
Partnerships 15
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Equity Offering 16
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc – Key Competitors 17
Axcella Health Inc – Key Employees 18
Axcella Health Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Oct 22, 2018: Axcella appoints Stephen Mitchener, PharmD, to senior vice president, chief business officer 20
Jun 27, 2018: Axcella Welcomes William D. Baird, and Cristina M. Rondinone to Board of Directors 21
May 31, 2018: Axcella Health Names Bill Hinshaw as President and Chief Executive Officer 23
Jan 03, 2018: Axcella Announces Appointment of David Epstein, Former CEO of Novartis Pharmaceuticals, as Chairman of its Board of Directors 24
Sep 14, 2017: Axcella Appoints Manu Chakravarthy, M.D., Ph.D., as Chief Medical Officer 25
Jun 14, 2017: Axcella Appoints Tony Tramontin, Ph.D., as Senior Vice President, Chief Scientific Officer 26
May 11, 2017: Axcella Announces the Appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., as Executive Vice President, Chief Strategy and Corporate Development Officer 27
Jan 03, 2017: Axcella Augments Leadership Team with the Appointment of Three Key Hires 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Axcella Health Inc, Pharmaceuticals & Healthcare, Key Facts 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc, Key Competitors 17
Axcella Health Inc, Key Employees 18

List of Figures
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Morphogenesis Inc-製薬・医療分野:企業M&A・提携分析
    Summary Morphogenesis Inc (Morphogenesis) is a novel cell and gene therapies developer. The company manufactures products based on distinct and synergistic technology platforms. It uses technologies such as immunefx cancer immunotherapies, the polymer antibody cell separation device, morphogenesis’ …
  • Sibur Holding:企業の戦略的SWOT分析
    Sibur Holding - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Information Services International-Dentsu Ltd (4812):企業の財務・戦略的SWOT分析
    Information Services International-Dentsu Ltd (4812) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Arcbest Corp.
    Arcbest Corp. - Strategy, SWOT and Corporate Finance Report Summary Arcbest Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Logitech International S.A.:企業の戦略・SWOT・財務情報
    Logitech International S.A. - Strategy, SWOT and Corporate Finance Report Summary Logitech International S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Inform Genomics Inc-医療機器分野:企業M&A・提携分析
    Summary Inform Genomics Inc (Inform Genomics) manufactures and markets genomic-based personalized medicine products for cancer and supportive care. The company’s onpart is a medicinal product, which is used for the treatment of decisions in patients, who receive chemotherapy for colorectal, breast, …
  • LegoChem Biosciences Inc (141080)-製薬・医療分野:企業M&A・提携分析
    Summary LegoChem Biosciences Inc (LCB) is a drug company that research and develops small molecule drugs. The company’s services include joint and contract research, chemical library package, compound synthesis and sales, and screening services. Its screening services include metabolic stability, pl …
  • Ind-Swift Ltd (INDSWFTLTD):企業の財務・戦略的SWOT分析
    Summary Ind-Swift Ltd (Ind-Swift), is a pharmaceutical company that develops, manufactures and markets finished goods dosage, active pharmaceutical ingredients and herbal products. The company offers products such as dispersible tablets, sustained release tablets, mouth dissolving tablets, chewable …
  • EP Petroecuador:企業の戦略的SWOT分析
    EP Petroecuador - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Matica Technologies AG:企業の戦略的SWOT分析
    Matica Technologies AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • K.P.R. Mill Ltd:企業の戦略・SWOT・財務分析
    K.P.R. Mill Ltd - Strategy, SWOT and Corporate Finance Report Summary K.P.R. Mill Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Fresenius Kabi AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company's product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and …
  • Color Genomics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Color Genomics, Inc. (Color) provides physician ordered genetic testing service that helps to identify hereditary cancer risk. The company’s clinical grade test provides actionable results that enable consumers and their doctors to create personalized screening and healthcare plan. Color ana …
  • Electricity Authority of Cyprus:発電所・企業SWOT分析
    Electricity Authority of Cyprus – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Golden Agri-Resources Ltd:企業の戦略・SWOT・財務情報
    Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sun A. Kaken Co. Ltd.:企業の戦略・SWOT・財務情報
    Sun A. Kaken Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sun A. Kaken Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • SOSINA Exploration Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Sosina Exploration Ltd (Sosina), formerly Odegaard UK Ltd is an oil and gas company that offers exploration and development services. The company identifies probable oil and gas accumulations in co-operation with partners within the oil and gas industries. It provides services in geological …
  • Pentagon Federal Credit Union:企業の戦略的SWOT分析
    Pentagon Federal Credit Union - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Dongkook Pharmaceutical Co Ltd (086450)-製薬・医療分野:企業M&A・提携分析
    Summary Dongkook Pharmaceutical Co Ltd (Dongkook) formerly known as UEC & Co. Ltd, is a pharmaceutical company which develops, manufacture and distributes pharmaceutical products, health care products and medical devices. It offers pharmaceutical products such as antibiotics, anodynes, vitamins, wou …
  • Propanc Biopharma Inc (PPCB):製薬・医療:M&Aディール及び事業提携情報
    Summary Propanc Biopharma Inc (Propanc), formerly Propanc Health Group Corp, is a clinical stage biopharmaceutical company, which manufactures products for the treat of metastatic, pancreatic, ovarian and colorectal cancers. The company’s lead product candidate, PRP, a once-a-day intravenous formula …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆